Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD-6277 in Inadequately Controlled Type 2 Diabetes
NCT06647550Phase 2Recruiting
- Sponsor
- Hyundai Pharmaceutical Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HD-6277 in type 2 diabetes mellitus (T2DM), sponsored by Hyundai Pharmaceutical Co., Ltd.. Started Dec 2024; status: recruiting.
02
Drugs
HD-6277
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06647550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06647550.